William D. Figg ET AL: "A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer", Clinical Cancer Research, 1 July 2001 (2001-07-01), page 1888, XP055488059, United States Retrieved from the Internet: URL:http://clincancerres.aacrjournals.org/ content/clincanres/7/7/1888.full.pdf (B1)

WO-A1-2014/152833 (B1)

CHADI NABHAN ET AL: "Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study", CLINICAL GENITOURINARY CANCER, vol. 12, no. 1, 1 February 2014 (2014-02-01), pages 27-32, XP055488660, US ISSN: 1558-7673, DOI: 10.1016/j.clgc.2013.09.001 (B1)

CHADI NABHAN ET AL: "The Role of IMiDs Alone or in Combination in Prostate Cancer", CLINICAL GENITOURINARY CANCER, vol. 10, no. 3, 1 September 2012 (2012-09-01), pages 141-146, XP055488662, US ISSN: 1558-7673, DOI: 10.1016/j.clgc.2012.03.005 (B1)

FANG, LUO ET AL.: 'The New Progress of Global Antineoplastic Drug R&D' PROCEEDINGS OF ANTICANCER DRUG SYMPOSIUM ON RESEARCH PROGRESS AND PERSONALIZED THERAPY 31 December 2013, pages 211 - 233, XP009508158 (B1)

FIGG W D ET AL: "A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 181, no. 3, 1 March 2009 (2009-03-01) , pages 1104-1113, XP025993684, ISSN: 0022-5347, DOI: 10.1016/J.JURO.2008.11.026 [retrieved on 2009-01-23] (B1)

GULLEY J L ET AL: "Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 180, no. 4, 1 October 2008 (2008-10-01), pages 1432-1437, XP025410332, ISSN: 0022-5347, DOI: 10.1016/J.JURO.2008.06.017 [retrieved on 2008-08-16] (B1)

Jeanny B Aragon-Ching ET AL: "Thalidomide analogues as anticancer drugs", Recent patents on anti-cancer drug discovery, 1 June 2007 (2007-06-01), pages 167-174, XP055474095, United Arab Emirates Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC2048745/ (B1)

MICHAEL E. JUNG ET AL: "Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 7, 8 April 2010 (2010-04-08), pages 2779-2796, XP055122595, ISSN: 0022-2623, DOI: 10.1021/jm901488g (B1)

PANG, RAN ET AL.: 'The Progress of Treatment of HRPC' CHINESE JOURNAL OF SURGERY OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE vol. 19, no. 1, 28 February 2013, pages 100 - 102, XP009505371 (B1)

US-A1- 2003 045 552 (B1)

US-A1- 2004 087 546 (B1)

US-A1- 2011 196 150 (B1)

US-A1- 2014 011 774 (B1)

US-A1- 2015 080 419 (B1)

WO-A1-02/059106 (B1)

WO-A1-2011/050962 (B1)

ANDRESSA ARDIANI ET AL: "Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway", ONCOTARGET, vol. 5, no. 19, 15 October 2014 (2014-10-15), XP055488676, United States ISSN: 1949-2553, DOI: 10.18632/oncotarget.2429 (B1)